Rakuten Investment Management Inc. Raises Stake in Amgen Inc. $AMGN

Rakuten Investment Management Inc. raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 266.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 99,999 shares of the medical research company’s stock after acquiring an additional 72,741 shares during the period. Rakuten Investment Management Inc.’s holdings in Amgen were worth $32,963,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the business. Dogwood Wealth Management LLC grew its holdings in shares of Amgen by 275.0% during the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 55 shares during the last quarter. Anfield Capital Management LLC lifted its stake in Amgen by 1,000.0% in the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after purchasing an additional 70 shares during the last quarter. Board of the Pension Protection Fund purchased a new stake in Amgen during the fourth quarter valued at about $26,000. Manning & Napier Advisors LLC boosted its position in Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after buying an additional 32 shares during the period. Finally, Olistico Wealth LLC bought a new position in shares of Amgen during the fourth quarter valued at about $33,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Trading Down 1.3%

NASDAQ AMGN opened at $350.53 on Tuesday. The stock has a market cap of $189.18 billion, a P/E ratio of 24.39, a price-to-earnings-growth ratio of 3.56 and a beta of 0.42. Amgen Inc. has a fifty-two week low of $267.83 and a fifty-two week high of $391.29. The stock has a 50 day simple moving average of $341.03 and a two-hundred day simple moving average of $345.86. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.77 by $0.38. The firm had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The business’s revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, analysts forecast that Amgen Inc. will post 22.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on AMGN. Guggenheim lowered their target price on Amgen from $351.00 to $340.00 and set a “neutral” rating for the company in a research note on Monday, May 4th. Freedom Capital upgraded Amgen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Wall Street Zen raised Amgen from a “hold” rating to a “buy” rating in a research note on Sunday. Rothschild & Co Redburn increased their price objective on Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a research note on Wednesday, February 18th. Finally, Barclays started coverage on shares of Amgen in a report on Friday, February 20th. They issued an “equal weight” rating and a $350.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Amgen presently has a consensus rating of “Hold” and an average target price of $354.12.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.85% of the company’s stock.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.